Navigation Links
A drug-dispensing contact lens
Date:7/21/2009

Taking eye drops multiple times a day can be difficult for patients to do, and because of blinking and tearing, as little as 1 to 7 percent of the dose is actually absorbed by the eye. Now, researchers led by Daniel Kohane, MD, PhD, director of the Laboratory for Biomaterials and Drug Delivery at Children's Hospital Boston, have developed special contact lenses that can gradually dispense a constant amount of medication to the eye, at adjustable rates. They describe their prototype lens in the July issue of Investigative Ophthalmology and Visual Science.

Although other groups have developed drug-releasing contact lenses, none have been able to achieve a constant, steady release of substantial amounts of drug; typically, a burst of drug is delivered in the first few hours, followed by rapidly dwindling amounts that are too low to be therapeutic. Kohane, collaborator Joseph Ciolino, MD, of the Massachusetts Eye and Ear Infirmary, and colleagues at the Department of Chemical Engineering at the Massachusetts Institute of Technology (MIT) created a two-layer contact lens with an inner drug-bearing biodegradable polymer film known as PLGA. Both PLGA and pHEMA (used for the coating) have been well studied and are already approved for ocular use by the Food and Drug Administration.

In laboratory testing, the prototype lenses dispensed ciprofloxacin (an antibiotic often used in eyedrops) for 30 days, the longest duration for which contact lenses are currently approved by the FDA; in some tests, the lenses continued releasing drug for up to 100 days. The amounts dispensed were sufficient to kill pathogens in a laboratory assay.

Kohane and Ciolino see applications in conditions such as glaucoma and dry-eye which require frequent daily eye drops. They have begun to test the lens in animals and plan to begin human testing as soon as possible. The technology recently won the Life Sciences track in MIT's 100K Entrepreneurship Competition
'/>"/>

Contact: Jamie Newton
james.newton@childrens.harvard.edu
617-919-3110
Children's Hospital Boston
Source:Eurekalert  

Page: 1 2

Related biology technology :

1. BioMS Medical to present at BioContact 2007
2. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
3. Dragon to Present at BioContact Quebec 2008
4. InNexus Biotechnology CEO to Present at BioContactQuebec 2008
5. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A drug-dispensing contact lens
A drug-dispensing contact lens
(Date:11/20/2009).... 20 Veridiam (www.veridiam.com) w...ompany category at the 2009 Workplace Excellence A...ociety for Human Resources Management and recogniz...ices. ,, Veridiam was one of nine winners, sele...es, honored at the recent awards ceremony. San Die...
(Date:11/20/2009)...OLM, November 20 Karolinska Develo...ent Fund (EIF) has entered into a,co-investment ag...ill be,managed by Karolinska Development and used ...e pharmaceutical and medical technology companies....nvestment fund. The agreement,represents EIF,s lar...
(Date:11/20/2009)... METTLER TOLEDO recently announced that Dr. Domini...he Role of Process Analytical Technology (PAT) in ...cember 1, 2009. , (PRWEB)...ess Analytical Technology (PAT) in Green Chemistry...cess Analytical Technology (PAT) case studies will...
(Date:11/19/2009)...19 Omeros Corporation (N... results for the third quarter ended September 30,...09, Omeros reported a net loss of $3.9 million, or...4 million, or $2.54 per share, for the same period...2009, the Company reported a net loss of $15.5 mil...
Breaking Biology Technology:Veridiam Wins Workplace Excellence Crystal Award in Mid-Size Company Category 2Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 2Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 3Process Analytical Technology (PAT) in Green Chemistry and Green Engineering 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8
...-Guided IMRT to Spare Healthy .... 16 Doctors at cancer,treatment centers in the U...head and neck cancer using RapidArc(TM) radiothera...VAR ). RapidArc was used to deliver ultra-precise,...T) significantly faster,than was previously possib...
...uticals, Inc. (Nasdaq: BCRX ) today announced tha...resident of BioCryst, will present,a corporate upd...e in New,York on Tuesday, September 23, 2008 at 2:... cast of the presentation may be accessed on,the B...esentation will be,archived for 30 days., About B...
... MIGENIX Inc. (the,"Company" or "MIGENIX") (TSX: M...gs for infectious diseases, reports financial resu...rovides a corporate update on its programs,and oth... Omiganan 1% gel (Omigard(TM)/CPI-226/MX-226; top...ted infections): Cadence Pharmaceuticals, Inc.,("C...
Other Biology Technology:Doctors in the US and Netherlands Using Fast RapidArc Radiotherapy Technology to Help Fight Cancer are Now Treating Tumors of the Head and Neck 2Doctors in the US and Netherlands Using Fast RapidArc Radiotherapy Technology to Help Fight Cancer are Now Treating Tumors of the Head and Neck 3BioCryst to Present at UBS 2008 Global Life Sciences Conference 2BioCryst to Present at UBS 2008 Global Life Sciences Conference 3MIGENIX Reports First Quarter Fiscal 2009 Financial Results 2MIGENIX Reports First Quarter Fiscal 2009 Financial Results 3MIGENIX Reports First Quarter Fiscal 2009 Financial Results 4MIGENIX Reports First Quarter Fiscal 2009 Financial Results 5MIGENIX Reports First Quarter Fiscal 2009 Financial Results 6MIGENIX Reports First Quarter Fiscal 2009 Financial Results 7MIGENIX Reports First Quarter Fiscal 2009 Financial Results 8MIGENIX Reports First Quarter Fiscal 2009 Financial Results 9MIGENIX Reports First Quarter Fiscal 2009 Financial Results 10MIGENIX Reports First Quarter Fiscal 2009 Financial Results 11
(Date:11/20/2009)...s about the health benefits of having a life partn... where amino acids known as cysteines are much mor...d up with other cysteines. , Now, researchers at... in Belgium, have discovered a new antioxidant sys...ppears in the Nov. 20 issue of the journal Scienc...
(Date:11/20/2009)...tists from the Marine Biogeochemistry and Geology ...ratory (NRL) organized and led a team of universit...n to initiate methane hydrate exploration in the B... sediment contribution to Arctic climate change. ,... as a research platform, three cross-shelf transec...
(Date:11/20/2009)...ial gene into yeast, researchers from Delft Univer...ee improvements in bioethanol production from agri...te and elimination of the major by-product glycero...ientific journal Applied and Environmental Microb...the yeast Saccharomyces cerevisiae from sugars obt...
Breaking Biology News(10 mins):Saving the single cysteine: New antioxidant system found 2International expedition investigates climate change, alternative fuels in Arctic 2Delft breakthrough in bioethanol production from agricultural waste 2Ranbaxy Receives Final Approval to Manufacture and Market Glycopyrrolate Tablets 55137 1Ranbaxy Receives Final Approval to Manufacture and Market Glycopyrrolate Tablets 55137 2Advanced Instruments Introduces Next Generation Web Site 13665 1Advanced Instruments Introduces Next Generation Web Site 13665 2CareTech to Provide Web Services to Blessing Health System 55135 1CareTech to Provide Web Services to Blessing Health System 55135 2CareTech to Provide Web Services to Blessing Health System 55135 3CareTech to Provide Web Services to Blessing Health System 55135 4
...ter wi-fi, music over the internet, pitch percepti... favorite salmon, detecting dangerous swimmers, he...hm and movement disorders, visualizing the sound o...to save manatees from collisions with boats. , T...at the 156th meeting of the Acoustical Society of ...
...t Professor of Biomedical Engineering and Orthoped...oundation New Scholar in Aging by The Ellison Medi...s invited to nominate two faculty members to submi...ed for this award after an internal competition. N...s being granted out of 97 applicants. Dr. Alsberg ...
...screened known drugs and identified small molecule...nes, which can have dangerous side effects. This n... from fibroblasts, a general cell type that is abu...including skin. , The study was published in the ...e journal Cell Stem Cell. , "Our study shows fo...
Other Biology News:Acoustical Meeting, Nov. 10-14, 2008 in Miami, Florida 2Acoustical Meeting, Nov. 10-14, 2008 in Miami, Florida 3Acoustical Meeting, Nov. 10-14, 2008 in Miami, Florida 4Acoustical Meeting, Nov. 10-14, 2008 in Miami, Florida 5Acoustical Meeting, Nov. 10-14, 2008 in Miami, Florida 6Acoustical Meeting, Nov. 10-14, 2008 in Miami, Florida 7Acoustical Meeting, Nov. 10-14, 2008 in Miami, Florida 8Acoustical Meeting, Nov. 10-14, 2008 in Miami, Florida 9Acoustical Meeting, Nov. 10-14, 2008 in Miami, Florida 10Acoustical Meeting, Nov. 10-14, 2008 in Miami, Florida 11Acoustical Meeting, Nov. 10-14, 2008 in Miami, Florida 12Acoustical Meeting, Nov. 10-14, 2008 in Miami, Florida 13Acoustical Meeting, Nov. 10-14, 2008 in Miami, Florida 14Acoustical Meeting, Nov. 10-14, 2008 in Miami, Florida 15Acoustical Meeting, Nov. 10-14, 2008 in Miami, Florida 16Case Western Reserve receives Ellison Medical Foundation New Scholar in Aging award 2Scripps research scientists identify compounds for stem-cell production from adult cells 2Scripps research scientists identify compounds for stem-cell production from adult cells 3
Rabbit Anti-Human CHYMOTRYPSIN Polyclonal Antibody, Unconjugated from AbD Serotec
rNeural Stem Cell (rNSC)Kit from AlphaGenix, Inc.
Sheep Anti-DEHYDROEPIANDROSTERONE (+DEAHS) Polyclonal Antibody, Unconjugated from AbD Serotec
4',6-diamidino-2-phenylindole, dihydrochloride (DAPI) *FluoroPure™ grade* from Molecular Probes (Invitrogen)
Biology Products: